Metabonomics: Systems biology in pharmaceutical research and development

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 3, 2004, Pages 265-272

  Lindon, John C ^a   Holmes, Elaine ^a   Nicholson, Jeremy K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Diagnosis; Drug safety; Genomics; Mass spectrometry; Metabonomics; Nuclear magnetic resonance; Proteomics; Transcriptomics

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTEIN; VASODILATOR AGENT; XENOBIOTIC AGENT;

ANALYTIC METHOD; CHEMOMETRICS; DATA ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG WITHDRAWAL; FOURIER TRANSFORM MASS SPECTROMETRY; GENE EXPRESSION PROFILING; HUMAN; MASS SPECTROMETRY; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN EXPRESSION; REVIEW; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLISM; MONITORING, PHYSIOLOGIC; PROTEOMICS; SOFTWARE; TECHNOLOGY, PHARMACEUTICAL;

ANIMALIA;

EID: 3242879742     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Human Genome Program, US Department of Energy: Genomics and its impact on science and society: A 2003 primer. (2003).
2. Scheel J, von Brevern MC, Horlein A, Fischer A, Schneider A, Bach A: Yellow pages to the transcriptome. Pharmacogenomics (2002) 3(6):791-807.
3. Kenyon GL, DeMarini DM, Fuchs E, Galas DJ, Kirsch JF, Leyh TS, Moos WH, Petsko GA, Ringe D, Rubin GM, Sheahan LC: Defining the mandate of proteomics in the post-genomics era: Workshop report. Mol Cell Proteomics (2002) 1(10):763-780.
4. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV et al: A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol (2001) 19(1):45-50.
5. Nicholson JK, Lindon JC Holmes E: 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic date. Xenobiotica (1999) 29(11):1181-1189.
6. Bugrim A, Nikolskaya T, Nikolsky Y: Early prediction of drug metabolism and toxicity: Systems biology approach and modeling. Drug Disc Today (2004) 9(3):127-135.
7. Nicholson JK, Wilson ID: Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 2(8):668-676.
8. Lindon JC, Nicholson JK, Holmes E, Everett JR: Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson (2000) 12(5):289-320.
9. Nicholson JK, Connelly J, Lindon JC, Holmes E: Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 1(2):153-161.
10. Lindon JC, Holmes E, Nicholson JK: So what's the deal with metabonomics? Anal Chem (2003) 75(17):384A-391A.
11. Plumb R, Granger J, Stumpf C, Wilson ID, Evans JA, Lenz EM: Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): Detection of strain, diurnal and gender differences. Analyst (2003) 128(7):819-823.
12. 1H NMR spectroscopy of intact liver and kidney: Optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal Biochem (2000) 282(1):16-23.
13. Lindon JC, Nicholson JK, Everett JR: NMR spectroscopy of biofluids. In: Ann Reports NMR Spectr. Webb GA (Ed), Academic Press, Oxford, UK (1999) 38:1-88.
14. Lindon JC, Nicholson JK, Wilson ID: Directly-coupled HPLC-NMR and HPLC-NMR-MS in pharmaceutical research and development. J Chromatogr B Biomed Sci Appl (2000) 748(1):233-258.
15. Coen M, Lenz EM, Nicholson JK, Wilson ID, Pognan F, Lindon JC: An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol (2003) 16(3):295-303.
16. Lamers RJ, Wessels EC, van de Sandt JJ, Venema K, Schaafsma G, van der Greef J, van Nesselrooij JH: A pilot study to investigate effects of inulin on Caco-2 cells through in vitro metabolic fingerprinting. J Nutr (2003) 133(10):3080-3084.
17. 1H NMR and MAS-NMR spectroscopy. Chem Res Toxicol (2002) 15(11):1351-1359.
18. Lindon JC, Holmes E, Nicholson JK: Pattern recognition methods and applications in biomedical magnetic resonance. Prog NMR Spectrosc (2001) 39(1):1-40.
19. Khandelwal P, Beyer CE, Lin Q, McGonigle P, Schechter LE, Bach AC: Nanoprobe NMR spectroscopy and in vivo microdialysis: New analytical methods to study brain neurochemistry. J Neurosci Methods (2004) 133(1-2):181-189.
20. 1H NMR spectroscopy using a 1 mm microlitre probe. Analyst (2002) 127(5):582-584.
21. 13C NMR spectroscopy of urine for metabonomic studies. Anal Chem (2002) 74(17):4588-4593.
22. Harrigan GG, LaPlante RH, Cosma GN, Cockerell G, Goodacre R, Maddox JF, Luyendyk JP, Ganey PE, Roth RA: Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: Contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett (2004) 146(3):197-205.
23. Schmitt J, Beekes M, Brauer A, Udelhoven T, Lasch P, Naumann D: Identification of scrapie infection from blood serum by Fourier transform infrared spectroscopy. Anal Chem (2002) 74(15):3865-3868.
24. Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E: Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Inf J (2001) 35(1):293-317.
25. 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers (2003) 8(3-4):240-271.
26. Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, Beckonert O, Ebbels TM, Reily MD, Robertson D, Stevens GJ et al: Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol (2003) 187(3):137-146.
27. 1H NMR-based metabonomic urinalysis. Chem Res Toxicol (2002) 15(11):1380-1386.
28. Ebbels T, Keun H, Beckonert O, Antti H, Bollard M, Holmes E, Lindon J, Nicholson J: Toxicity classification from metabonomic data using a density superposition approach: 'CLOUDS'. Anal Chim Acta (2003) 490(1-2):109-122.
29. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK: Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004): in press.
30. Griffin JL, Sang E, Evens T, Davies K, Clarke K: Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy. FEBS Lett (2002) 530(1-3):109-116.
31. Nicholls AW, Mortishire-Smith RJ, Nicholson JK: NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol (2003) 16(11):1395-1404.
32. Waters NJ, Holmes E, Williams A, Waterfield CJ, Farrant RD, Nicholson JK: NMR and pattern recognition studies on the time-related metabolic effects of α-naphthylisothiocyanate on liver, urine, and plasma in the rat: An integrative metabonomic approach. Chem Res Toxicol (2001) 14(10):1401-1412.
33. Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID: Integrated application of transcriptomics and metabonomics yields now insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal (2004) 35(1):93-105.
34. 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies. Magn Reson Med (1998) 39(6):869-877.
35. 1H nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumour tissues. Anal Commun (1998) 35(3):113-115.
36. 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal (1998) 17(1):125-132.
37. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci (2003) 212(1-2):21-30.
38. 1H-NMR-based metabonomics. Nat Med (2002) 8(12):1439-1444.